The newest edition of BioCentury This Week television explores the molecular diagnostic conundrum — where tests are expected to show the kind of clinical evidence required for drugs, but without the reward system that exists for therapeutics.
Dr. David Parkinson of venture firm New Enterprise Associates, and former CEO of cancer diagnostics play Nodality, brings the clinical and investor perspective to the “kind of world diagnostic companies need to move into.”
Kimberly Popovits, Chairman, President and CEO of Genomic Health, brings the ground-level view from a company whose diagnostics are now used to make treatment decisions in cancer.
In conversation with Washington Editor Steve Usdin, they explore:
|•||How “patient value” and “payer value” have different definitions|
|•||How molecular diagnostics need to be seen “through a different lens” for reimbursement|
|•||Whether developers of 21st century diagnostics have the expertise to produce evidence of clinical effectiveness sought by regulators|
|•||Why the runway to develop molecular diagnostics is longer than anyone had anticipated|
|•||Whether companion diagnostics — the “tight integration of therapeutics and diagnostics development” — will be at the core of the MDx business model in the long run|
NOTICE: BioCentury Publications, Inc., and WUSA-TV own the copyright to the program content on “BioCentury This Week,” and except for limited use of these links to the BioCenturytv.com website, BioCentury and WUSA prohibit hosting of BioCentury This Week program content by unauthorized third parties or posting of BioCentury This Week content to any unauthorized third party websites such as YouTube. Other BioCenturytv.com content and all trademarks are the property of BioCentury or WUSA-TV or other third parties.